Ministérios das Finanças e da Administração Pública e da Saúde Despacho Considerando que o plafond previsto no Orçamento de Estados de 2011 para o Serviço Nacional de Saúde prevê uma redução de 6,4%, que decorre das medidas identificadas e em implementação nos Cuidados de Saúde Primários, nos Cuidados Hospitalares, nos Programas verticais e nos serviços [...]
Adult-Onset Still Disease As the Cause of Fever of Unknown Origin Marco DIOGO, João SOARES, Teresa PIMENTEL, Adelina FERREIRA Resumo: A síndrome febril indeterminada permanece um dos grandes desafios com até 50% dos casos a permanecerem sem diagnóstico. A doença de Still do adulto caracteriza-se tipicamente por febre elevada, artralgias, rash, faringite e serosite, linfadenopatias e hepatoesplenomegalia, com [...]
Claudia Ribeiro*, Luis Moreira**,Augusta Silveira***, Isabel Silva****, Juan Gestal*****, Carlos Vasconcelos****** Abstract Aim:The major purpose of this study was to evaluate alternative automated methods of collecting data on health related quality of life (HR-QoL). In order to achieve this, we developed a study with the following objectives: (1) to evaluated the feasibility of electronic version in [...]
Arthritis Research & Therapy 2010, 12:R191 doi:10.1186/ar3161 Anna R Broder (abroder@montefiore.org) Jonathan N Tobin (JNTobin@CDNetwork.org) Chaim Putterman (chaim.putterman@einstein.yu.edu) Abstract: Introduction: We compared the odds of vitamin D deficiency in three chronic diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type 2 diabetes (T2DM), adjusting for medications, demographics, and laboratory parameters, common to all three diseases. We also designed multivariate models [...]
Keystone, E, Emery, P, Peterfy, C G, Tak, P P, Cohen, S, Genovese, M C, Dougados, M, Burmester, G R, Greenwald, M, Kvien, T K, Williams, S, Hagerty, D, Cravets, M W, Shaw, T Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Objective: To [...]
Bert Vander Cruyssen (Bert.VanderCruyssen@Ugent.be) Patrick Durez (Patrick.Durez@ruma.ucl.ac.be) Rene Westhovens (Rene.westhovens@uz.kuleuven.ac.be) Marie-Joelle Kaiser (Mjkaiser@chu.ulg.ac.be) Ilse Hoffman (Ilse.Hoffman@skynet.be) Filip De Keyser (Filip.Dekeyser@Ugent.be) The MIRA Study Group (not@valid.com) Abstract Introduction: This study describes the results of the Belgian “MabThera In Rheumatoid Arthritis (MIRA)” registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. Methods: All Belgian rheumatologists [...]
Leigh D Church (L.D.Church@bham.ac.uk) Andrew D Filer (A.D.Filer@bham.ac.uk) Esther Hidalgo (Hidalgoester@gmail.com) Katherine A Howlett (K.A.Howlett@bham.ac.uk) Andrew MC Thomas (Andrew.Thomas@roh.nhs.uk) Stephen Rapecki (Stephen.Rapecki@ucb.com) Dagmar Scheel-Toellner (D.Scheel@bham.ac.uk) Christopher D Buckley (C.D.Buckley@bham.ac.uk) Karim Raza (k.raza@bham.ac.uk) Abstract: Introduction. Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to systematically analyse the phenotype, cytokine profile and frequency of interleukin-17 (IL-17) producing CD4-positive [...]
Sharon Van Doornum (svd@unimelb.edu.au) Caroline Brand (caroline.brand@mh.org.au) Vijaya Sundararajan (vijaya.sundararajan@med.monash.edu.au) Andrew E Ajani (andrew.ajani@mh.org.au) Ian P Wicks (ian.wicks@mh.org.au) Abstract Introduction: The 30-day case fatality rate after acute myocardial infarction (MI) for rheumatoid arthritis (RA) patients is twice that of the general population. This study compared the frequency and timeliness of early reperfusion therapy and treatment with secondary prevention medications after acute MI in [...]
Nature Clinical Practice Rheumatology 4, 624 (2008). Ver artigo completo
Arthritis Research & Therapy Frederik Kreiner (frederik.kreiner@me.com) Henrik Galbo (hga@sund.ku.dk) Abstract Introduction: To elucidate in polymyalgia rheumatica (PMR) the role of tumor necrosis factor (TNF) α and the therapeutic potential of blockade with soluble TNF-α receptor, we carried out the first randomized controlled trial with etanercept in PMR. Methods: Twenty newly diagnosed, glucocorticoid (GC) naïve patients with PMR and 20 [...]